Tagged with PPP

Mexico. B. Braun Paulina Escobedo, general manager of B. Braun Medical Mexico, provides insights into the impressive development of this division since it was set up in the country in 2011, while the company will introduce its pharma product portfolio in Mexico in the upcoming months. She also documents the comprehensive partnership approach…

Switzerland Walter Steinlin describes the Federal Commission of Technology and Innovation as a catalyst for turning research into innovation. Based in Bern, Switzerland, the commission funds research institutes in corporate projects, and provides mentorship and coaching support for start-ups. Could you give our international audience an overview of the Federal Commission…

Innovation Professor Mark Ferguson, Director General of Science Foundation Ireland and Chief Scientific Advisor to the Government of Ireland, highlights Ireland’s recent spectacular success in fostering research and innovation; the government’s strategy to further promote Irish science, Innovation 2020; the priority of building academia-industry partnerships; and his mission to turn Ireland…

Pharma The executive director of A*STAR’s Biomedical Research Council, Dr. Benjamin Seet highlights several remarkable milestones that the organization has been able to achieve since its inception, while underscoring how cultivating deep levels of expertise will carry Singapore’s biomedical sciences sector into its next phase of development. In a few words,…

Pharma Professor Dr. Susan M. Gasser of the Friedrich Miescher Institute for Biomedical Research describes FMI’s fundamental connection between academia and industry in Switzerland, the effects of the foundation’s research, notably on Novartis, and future projects in the making. Could you begin by introducing both yourself and your institute to our…

PPP Known as “Ireland’s university of Enterprise,” Dublin City University’s research and educational philosophy is very much informed by the institution’s strong partnerships and collaborations with the private sector. Professor Brian MacCraith discusses the institutions’ unique approach to academic-private collaborations and some of the initiatives currently underway in the life science…

Pharma Patricia Ostrosky, general director of the Institute of Biomedical Research in Mexico, details current research subjects and calls for greater collaboration between Mexican universities and the pharmaceutical industry to bring more life-changing innovation to patients. Could you please provide our readers with a general overview of the Institute of Biomedical…

Pharma PwC Italy’s Rodrigue G. Schübelin talks maintaining Italy’s impressive growth in pharma production, R&D incentives, public-private collaboration, and PwC’s role within the Italian healthcare ecosystem. Italy’s pharmaceutical production increased by 38 percent from 2009 to 2014; what steps does the industry need to take to keep performing at this level?…

Pharma Lyonbiopole was established in 2005 as a cluster designed to support the local business community focused on infectious diseases and microbiology. Philippe Archinard, the Biopole’s president, traces the evolution of the cluster over the last decade while underscoring the critical importance of transparency and collaboration between government, industry and academia.…

Pharma The Dedicated Chair of the Pharmaceutical Committee of the Association of Health Insurance Companies speaks about drug pricing procedures, the partnership with the pharmaceutical industry, as well as her overarching vision for the organization. The Association of Health Insurance Companies of the Czech Republic (CR CAP) was established in 1997…

Pharma Luigi Boggio, President of Assobiomedica, the association representing the medtech industry, and MD of B. Braun Italy, calls on the Italian government to implement a national system that measures the impact of medtech innovations. What are the exact activities of Assobiomedica and what are your main priorities as President? The…

Pharma The AIFP’s Jakub Dvořáček explains the recently launched tool for information disclosure between pharmaceutical companies and doctors, highlighting the significance it holds for industry and country. Furthermore, he reviews the Czech Republic’s attractiveness as a location for pharma companies. When we met you in 2012, you named re-exporting and a…